Exploring the Comprehensive Kozak Sequence Landscape for AAV Production in Sf9 System

Area of Science:

• Biotechnology and Gene Therapy
• Virology
• Molecular Biology

Background:

• Recombinant Adeno-associated virus (rAAV) is crucial for gene therapy, necessitating scalable manufacturing.
• The Baculovirus/Sf9 system offers high yield but often results in lower biological potency due to altered capsid stoichiometry.
• Optimizing rAAV capsid composition is key to enhancing both production yield and infectivity.

Purpose of the Study:

• To introduce the concept of "fitness" for Adeno-associated virus (AAV) capsids, defined by packaging and transduction efficiency.
• To develop a novel Directed Evolution (DE) protocol for optimizing the structural and biological fitness of Sf9-manufactured rAAV.
• To identify optimal AAV capsid compositions for improved gene therapy vector production.

Main Methods:

• Developed a Directed Evolution (DE) protocol using insect Sf9 cells for rAAV production.
• Created a combinatorial capsid library for packaging in Sf9 cells.
• Screened the library for high infectivity in human C12 cells, followed by Next-Generation Sequencing (NGS) and in silico analysis.

Main Results:

• The DE protocol successfully identified "fit" AAV capsids with high production yield and superior transduction efficiencies.
• A single round of DE selection, combined with NGS and in silico analysis, pinpointed optimal VP1 translation initiation sites (Kozak sequences).
• This approach allows for the optimization of rAAV capsids for specific serotypes.

Conclusions:

• The novel DE protocol effectively enhances the structural and biological fitness of rAAV produced in insect cells.
• Optimizing AAV capsid stoichiometry through DE is critical for improving gene therapy vector potency.
• This strategy provides a powerful tool for scalable and efficient rAAV manufacturing for gene therapy.